Abstract
Get full access to this article
View all access options for this article.
References
1.Audentes Therapeutics, an Astellas Company. Audentes therapeutics provides update on the ASPIRO clinical trial evaluating AT132 in patients with X-linked myotubular myopathy . 2020. https://www.audentestx.com/press_release/audentes-therapeutics-provides-update-on-the-aspiro-clinical-trial-evaluating-at132-in-patients-with-x-linked-myotubular-myopathy/ (last accessed
August 26 , 2020
).
2.Audentes Therapeutics, an Astellas Company . Q1/FY2020 financial results ended June 30, 2020. 2020. https://sw4503.swcms.net/en/business-results/inframe/main/0/teaserItems1/0/linkList/02/link/1q2020_pre_en.pdf (last accessed
August 26 , 2020
).
3.
Paulk, N. Gene therapy: it's time to talk about high-dose AAV. Genetic Engineering & Biotechnology News. 2020. https://www.genengnews.com/commentary/gene-therapy-its-time-to-talk-about-high-dose-aav/ (last accessed
August 28 , 2020
).
4.BioMarin Pharmaceutical . BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A. 2020. https://investors.biomarin.com/2020-08-19-BioMarin-Receives-Complete-Response-Letter-CRL-from-FDA-for-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Severe-Hemophilia-A (last accessed
August 26 , 2020
).
5.
Carvalho, J. ‘Huge Step Back’ for Hemophilia Gene Therapy, Expert Says of FDA Delay on Roctavian. Hemophilia News Today. 2020. https://hemophilianewstoday.com/2020/08/21/roctavian-fda-delay-huge-setback-hemophilia-gene-therapy-guy-young-interview/ (last accessed
August 26 , 2020
).
6.FUJIFILM Diosynth Biotechnologies. FUJIFILM Diosynth Biotechnologies Breaks Ground For Advanced Therapies Innovation Center in Texas. 2020 . https://www.prnewswire.com/news-releases/fujifilm-diosynth-biotechnologies-breaks-ground-for-advanced-therapies-innovation-center-in-texas-301115087.html (last accessed
August 24 , 2020
).
7.Sorrento Therapeutics and SmartPharm Therapeutics . Sorrento Enters Into Merger Agreement to Acquire SmartPharm and Develop Pipeline of Gene-Encoded Therapeutic Antibodies, Starting With Neutralizing Antibodies to Treat COVID-19 and Cancer Therapeutics. 2020. https://www.globenewswire.com/news-release/2020/08/20/2081668/0/en/Sorrento-Enters-Into-Merger-Agreement-to-Acquire-SmartPharm-and-Develop-Pipeline-of-Gene-Encoded-Therapeutic-Antibodies-Starting-With-Neutralizing-Antibodies-to-Treat-COVID-19-and-.html (last accessed
August 24 , 2020
).
8.Forge Biologics. Forge Biologics Launches with $40 Million Series A Financing to Manufacture and Develop Gene Therapies. 2020 . https://www.businesswire.com/news/home/20200721005169/en/Forge-Biologics-Launches-40-Million-Series-Financing (last accessed
August 24 , 2020
).
9.Passage Bio. Passage Bio Reports Second Quarter 2020 Financial Results and Recent Business Highlights. 2020 . https://investors.passagebio.com/news-releases/news-release-details/passage-bio-reports-second-quarter-2020-financial-results-and (last accessed
August 25 , 2020
).
10.Passage Bio. Form 10-Q Quarterly Report . Filed August 13, 2020, with the U.S. Securities and Exchange Commission. https://investors.passagebio.com/static-files/f26174b6-f8ab-4b8d-bb26-4443950731ec (last accessed
August 25 , 2020
).
11.
Philippidis, A. AGTC Sets Sights on Late-Stage Retinitis Pigmentosa Gene Therapy Trial. Genetic Engineering & Biotechnology News. 2020. https://www.genengnews.com/gen-edge/agtc-sets-sights-on-late-stage-retinitis-pigmentosa-gene-therapy-trial/ (last accessed
August 26 , 2020
).
12.
Song C, Dufour VL, Cideciyan AV, et al. Dose Range Finding Studies with Two RPGR Transgenes in a Canine Model of X-Linked Retinitis Pigmentosa Treated with Subretinal Gene Therapy. Human Gene Therapy 2020. https://doi.org/10.1089/hum.2019.337 (last accessed
August 26 , 2020
).